Cargando…
A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma
Although costimulatory molecules have been shown to boost antitumor immune responses, their significance in stomach adenocarcinoma (STAD) remains unknown. The purpose of this study was to examine the gene expression patterns of costimulatory molecule genes in patients with STAD and develop a predict...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353527/ https://www.ncbi.nlm.nih.gov/pubmed/35935979 http://dx.doi.org/10.3389/fimmu.2022.928742 |
_version_ | 1784762883858497536 |
---|---|
author | Chen, Bangjie Yao, Yong Mao, Deshen Li, Conghan Wang, Xingyu Sheng, Shuyan Zhang, Lizhi Wang, Xinyi Chen, Sanwei Xu, Wentao Deng, Jianyi Sun, Chenyu Zhou, Qin Lowe, Scott Bentley, Rachel Shao, Wei Li, Haiwen |
author_facet | Chen, Bangjie Yao, Yong Mao, Deshen Li, Conghan Wang, Xingyu Sheng, Shuyan Zhang, Lizhi Wang, Xinyi Chen, Sanwei Xu, Wentao Deng, Jianyi Sun, Chenyu Zhou, Qin Lowe, Scott Bentley, Rachel Shao, Wei Li, Haiwen |
author_sort | Chen, Bangjie |
collection | PubMed |
description | Although costimulatory molecules have been shown to boost antitumor immune responses, their significance in stomach adenocarcinoma (STAD) remains unknown. The purpose of this study was to examine the gene expression patterns of costimulatory molecule genes in patients with STAD and develop a predictive signature to aid in therapy selection and outcome prediction. We used 60 costimulatory family genes from prior research to conduct the first complete costimulatory molecular analysis in patients with STAD. In the two study groups, consensus clustering analysis based on these 60 genes indicated unique distribution patterns and prognostic differences. Using the least absolute shrinkage and selection operator and Cox regression analysis, we identified nine costimulatory molecular gene pairs (CMGPs) with prognostic value. With these nine CMGPs, we were able to develop a costimulatory molecule-related prognostic signature that performed well in an external dataset. For the patients with STAD, the signature was proven to be a risk factor independent of the clinical characteristics, indicating that this signature may be employed in conjunction with clinical considerations. A further connection between the signature and immunotherapy response was discovered. The patients with high mutation rates, an abundance of infiltrating immune cells, and an immunosuppressive milieu were classified as high-risk patients. It is possible that these high-risk patients have a better prognosis for immunotherapy since they have higher cytolytic activity scores and immunophenoscores of CTLA4 and PD-L1/PD-L2 blockers. Therefore, our signature may help clinicians in assessing patient prognosis and developing treatment plans. |
format | Online Article Text |
id | pubmed-9353527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93535272022-08-06 A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma Chen, Bangjie Yao, Yong Mao, Deshen Li, Conghan Wang, Xingyu Sheng, Shuyan Zhang, Lizhi Wang, Xinyi Chen, Sanwei Xu, Wentao Deng, Jianyi Sun, Chenyu Zhou, Qin Lowe, Scott Bentley, Rachel Shao, Wei Li, Haiwen Front Immunol Immunology Although costimulatory molecules have been shown to boost antitumor immune responses, their significance in stomach adenocarcinoma (STAD) remains unknown. The purpose of this study was to examine the gene expression patterns of costimulatory molecule genes in patients with STAD and develop a predictive signature to aid in therapy selection and outcome prediction. We used 60 costimulatory family genes from prior research to conduct the first complete costimulatory molecular analysis in patients with STAD. In the two study groups, consensus clustering analysis based on these 60 genes indicated unique distribution patterns and prognostic differences. Using the least absolute shrinkage and selection operator and Cox regression analysis, we identified nine costimulatory molecular gene pairs (CMGPs) with prognostic value. With these nine CMGPs, we were able to develop a costimulatory molecule-related prognostic signature that performed well in an external dataset. For the patients with STAD, the signature was proven to be a risk factor independent of the clinical characteristics, indicating that this signature may be employed in conjunction with clinical considerations. A further connection between the signature and immunotherapy response was discovered. The patients with high mutation rates, an abundance of infiltrating immune cells, and an immunosuppressive milieu were classified as high-risk patients. It is possible that these high-risk patients have a better prognosis for immunotherapy since they have higher cytolytic activity scores and immunophenoscores of CTLA4 and PD-L1/PD-L2 blockers. Therefore, our signature may help clinicians in assessing patient prognosis and developing treatment plans. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353527/ /pubmed/35935979 http://dx.doi.org/10.3389/fimmu.2022.928742 Text en Copyright © 2022 Chen, Yao, Mao, Li, Wang, Sheng, Zhang, Wang, Chen, Xu, Deng, Sun, Zhou, Lowe, Bentley, Shao and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Chen, Bangjie Yao, Yong Mao, Deshen Li, Conghan Wang, Xingyu Sheng, Shuyan Zhang, Lizhi Wang, Xinyi Chen, Sanwei Xu, Wentao Deng, Jianyi Sun, Chenyu Zhou, Qin Lowe, Scott Bentley, Rachel Shao, Wei Li, Haiwen A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma |
title | A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma |
title_full | A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma |
title_fullStr | A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma |
title_full_unstemmed | A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma |
title_short | A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma |
title_sort | signature based on costimulatory molecules for the assessment of prognosis and immune characteristics in patients with stomach adenocarcinoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353527/ https://www.ncbi.nlm.nih.gov/pubmed/35935979 http://dx.doi.org/10.3389/fimmu.2022.928742 |
work_keys_str_mv | AT chenbangjie asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT yaoyong asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT maodeshen asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT liconghan asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT wangxingyu asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT shengshuyan asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT zhanglizhi asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT wangxinyi asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT chensanwei asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT xuwentao asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT dengjianyi asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT sunchenyu asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT zhouqin asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT lowescott asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT bentleyrachel asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT shaowei asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT lihaiwen asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT chenbangjie signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT yaoyong signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT maodeshen signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT liconghan signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT wangxingyu signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT shengshuyan signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT zhanglizhi signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT wangxinyi signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT chensanwei signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT xuwentao signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT dengjianyi signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT sunchenyu signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT zhouqin signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT lowescott signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT bentleyrachel signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT shaowei signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma AT lihaiwen signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma |